Plasma homocysteine status in patients with ankylosing spondylitis

doi:10.1007/s10067-006-0396-x

中山醫學大學機構典藏 CSMUIR > 醫學院 > 免疫學研究所 > 期刊論文 > Item 310902500/11777

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/11777

Title:	Plasma homocysteine status in patients with ankylosing spondylitis
Authors:	Wei, James Cheng-Chung Jan, Ming-Shiou Yu, Chen tung Huang, Yi-Chia Yang, Chi-Chiang Tsou, Hsi-Kai
Contributors:	中山醫學大學
Keywords:	Ankylosing spondylitis;Folic acid;Homocysteine;Vitamin
Date:	2007
Issue Date:	2015-07-29T04:24:33Z (UTC)
ISSN:	0770-3198
Abstract:	Homocysteine (Hcy), a sulfur-containing amino acid, is eliminated through B vitamins-dependent pathways. Hyperhomocysteinemia has been found to be an independent risk factor for atherosclerotic cardiovascular, cerebrovascular, and peripheral vascular diseases. Recently, psoriasis, lupus, and rheumatoid arthritis were reported to be associated with hyperhomocysteinemia. This study was aimed to evaluate the changes of plasma Hcy level before and after sulfasalazine and MTX therapy in patients with ankylosing spondylitis (AS). One hundred and two patients with AS and ten normal controls were enrolled in the cross-sectional case-control study. Fasting plasma Hcy levels were determined by ELISA kits (IMX, Abbott). Hcy levels were compared to their Bath AS disease activity index (BASDAI) and the usage of sulfasalazine and/or MTX. Active disease was defined by BASDAI as more than 3 in a 10-cm scale with ESR >20 mm/h. For those patients with plasma Hcy >or=15 micromol/l, a perspective trial of daily supplement of vitamin B-12 0.5 mg, B-6 50 mg, and folic acid 5 mg for 2 weeks were also tested for the efficacy. Plasma Hcy level increased significantly in AS patients under sulfasalazine (10.4+/-3.8 micromol/l, p<0.05), MTX (11.9+/-4.7, p<0.05) and sulfasalazine/MTX combination treatment (11.2+/-2.6, p<0.05) compared with normal controls (8.6+/-1.2 micromol/l) and AS patients without DMARD(9.4+/- 2.6 micromol/l). No correlation between disease activity and plasma Hcy level was found. Daily supplement of vitamin B-12 0.5 mg, B-6 50 mg, and folic acid 5 mg can lower Hcy level in 2 weeks (32.3+/-24.0 vs 15.6+/-11.1 micromol/l, p=0.007). Plasma homocysteine level did significantly increase in AS patients under sulfasalazine or MTX treatment. B-vitamins should be considered as a routine supplementation for patients who underwent sulfasalazine and/or MTX treatment. Further longitudinal studies are required to confirm the conclusions. Plasma homocysteine status in patients with ankylosing spondylitis (PDF Download Available). Available from: http://www.researchgate.net/publication/6771373_Plasma_homocysteine_status_in_patients_with_ankylosing_spondylitis [accessed Jul 29, 2015].
URI:	https://ir.csmu.edu.tw:8080/ir/handle/310902500/11777 http://dx.doi.org/10.1007/s10067-006-0396-x
Relation:	Clinical Rheumatology (Impact Factor: 1.77). 05/2007; 26(5):739-42.
Appears in Collections:	[免疫學研究所] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html	期刊論文	0Kb	HTML	262	View/Open

View Licence

Loading...